The clinical education
Testosterone can help the right woman. A low number does not make the diagnosis.
Sexual desire is shaped by the brain, body, relationship, context, comfort, medications, health, sleep, and life experience. Testosterone may be one part of care for a specific diagnosis. It is not a universal answer for every change in desire, arousal, energy, or connection.
Desire naturally varies across a lifetime. A change becomes a clinical concern when it is persistent or recurrent, is experienced as unwanted, and causes personal distress. Hypoactive sexual desire disorder, or HSDD, is diagnosed through a careful biopsychosocial assessment. It is not diagnosed from a testosterone value, and no laboratory cutoff reliably distinguishes women with HSDD from women without it.
Some women also experience desire as responsive rather than spontaneous. They may not think about sex “out of the blue,” yet can become interested after affectionate contact, emotional connection, or pleasurable stimulation begins. That pattern is not automatically a disorder. The question is whether the woman is distressed by a meaningful change and whether the sexual context is safe, wanted, and capable of becoming pleasurable.
Testosterone is a treatment for a diagnosis, not a verdict attached to a laboratory number.
Where the evidence is strongest
Professional consensus supports systemic testosterone as an evidence-based option for appropriately evaluated postmenopausal women with HSDD. Trials show a moderate average benefit in desire, arousal, orgasm, pleasure, responsiveness, sexual self-image, and sexually satisfying events, together with less sexual concern. The average benefit matters, but it is not a promise that testosterone will restore a previous self or resolve pain, relationship strain, fatigue, medication effects, or every feature of sexual function.
As of 2026, the United States has no testosterone product specifically approved by the Food and Drug Administration for women. When it is prescribed for HSDD, clinicians generally use a carefully adjusted fraction of a transdermal product formulated for men. This is off-label prescribing. It requires clear counseling, female-appropriate dosing, symptom follow-up, and laboratory monitoring.
What laboratory testing can and cannot do
Total testosterone and sex hormone-binding globulin, or SHBG, are typically measured before treatment. These values help establish a baseline, identify unusually high levels or factors that may affect treatment response, and support safe monitoring. They do not confirm HSDD, and treatment should not be used to chase a number above the normal physiologic range for premenopausal women.
Guidelines favor transdermal therapy that can be adjusted and monitored. Compounded products can vary in concentration and lack the same evidence for effectiveness and safety. Pellets and injections may produce levels above the physiologic range and can be difficult or impossible to titrate once administered. Oral testosterone formulations are also not recommended for this purpose.
Important limits in what we know
Short-term trials using physiologic doses have not shown the same pattern of serious adverse events seen with excessive androgen exposure. Even so, long-term safety beyond the duration of available trials remains uncertain, and women at high cardiometabolic risk were often excluded from research. Treatment decisions should account for cardiovascular health, breast health, liver function, other medications, and the individual woman’s priorities.
A thoughtful sexual-health plan does not begin with “your testosterone is low.” It begins with “tell me what changed, what this means to you, and what sex feels like now.”